Advanced

Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity.

Sämgård, Kajsa; Zetterberg, Henrik; Blennow, Kaj; Hansson, Oskar LU ; Minthon, Lennart LU and Londos, Elisabet LU (2010) In International Journal of Geriatric Psychiatry 25. p.403-410
Abstract
OBJECTIVES: The aim of this longitudinal study was to test the hypothesis that CSF biomarkers in AD patients also may be forward-looking measures that are associated not only with the degree and profile of cognitive impairment but also with changes in cognition over time. METHODS: Here, we assessed the association of CSF Abeta42, T-tau and P-tau with neuropsychological scores of disease severity, as well as the rate of disease progression, in 142 patients with Alzheimer's disease. All patients were part of a 3-year prospective longitudinal treatment study. RESULTS: A more rapid progress in MMSE score reduction was seen in AD patients with T-tau levels higher than the upper quartile (800 ng/L) compared with Alzheimer's disease patients with... (More)
OBJECTIVES: The aim of this longitudinal study was to test the hypothesis that CSF biomarkers in AD patients also may be forward-looking measures that are associated not only with the degree and profile of cognitive impairment but also with changes in cognition over time. METHODS: Here, we assessed the association of CSF Abeta42, T-tau and P-tau with neuropsychological scores of disease severity, as well as the rate of disease progression, in 142 patients with Alzheimer's disease. All patients were part of a 3-year prospective longitudinal treatment study. RESULTS: A more rapid progress in MMSE score reduction was seen in AD patients with T-tau levels higher than the upper quartile (800 ng/L) compared with Alzheimer's disease patients with lower T-tau levels (p = 0.008). We also found that individuals with T-tau > 800 ng/L performed worse in total scores and especially in memory and orientation when assessed with MMSE and ADAS cog than patients with T-tau <800 ng/L. Similar results were obtained for P-tau. No associations were seen between Abeta42 and cognitive scores or disease progression. DISCUSSION: These findings support the hypothesis that increased levels of T-tau reflect the intensity of the disease and are associated with a more rapid disease progress. Copyright (c) 2009 John Wiley & Sons, Ltd. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
International Journal of Geriatric Psychiatry
volume
25
pages
403 - 410
publisher
John Wiley and Sons Ltd
external identifiers
  • wos:000276670000010
  • pmid:19650161
  • scopus:77949506958
ISSN
1099-1166
DOI
10.1002/gps.2353
language
English
LU publication?
yes
id
87f60c8f-e0f4-4fd0-ac74-cdee84f7cb17 (old id 1470139)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19650161?dopt=Abstract
date added to LUP
2009-09-04 11:16:07
date last changed
2018-10-03 10:42:51
@article{87f60c8f-e0f4-4fd0-ac74-cdee84f7cb17,
  abstract     = {OBJECTIVES: The aim of this longitudinal study was to test the hypothesis that CSF biomarkers in AD patients also may be forward-looking measures that are associated not only with the degree and profile of cognitive impairment but also with changes in cognition over time. METHODS: Here, we assessed the association of CSF Abeta42, T-tau and P-tau with neuropsychological scores of disease severity, as well as the rate of disease progression, in 142 patients with Alzheimer's disease. All patients were part of a 3-year prospective longitudinal treatment study. RESULTS: A more rapid progress in MMSE score reduction was seen in AD patients with T-tau levels higher than the upper quartile (800 ng/L) compared with Alzheimer's disease patients with lower T-tau levels (p = 0.008). We also found that individuals with T-tau &gt; 800 ng/L performed worse in total scores and especially in memory and orientation when assessed with MMSE and ADAS cog than patients with T-tau &lt;800 ng/L. Similar results were obtained for P-tau. No associations were seen between Abeta42 and cognitive scores or disease progression. DISCUSSION: These findings support the hypothesis that increased levels of T-tau reflect the intensity of the disease and are associated with a more rapid disease progress. Copyright (c) 2009 John Wiley &amp; Sons, Ltd.},
  author       = {Sämgård, Kajsa and Zetterberg, Henrik and Blennow, Kaj and Hansson, Oskar and Minthon, Lennart and Londos, Elisabet},
  issn         = {1099-1166},
  language     = {eng},
  pages        = {403--410},
  publisher    = {John Wiley and Sons Ltd},
  series       = {International Journal of Geriatric Psychiatry},
  title        = {Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity.},
  url          = {http://dx.doi.org/10.1002/gps.2353},
  volume       = {25},
  year         = {2010},
}